Paudyal Ramesh, Konar Amaresha Shridhar, Obuchowski Nancy A, Hatzoglou Vaios, Chenevert Thomas L, Malyarenko Dariya I, Swanson Scott D, LoCastro Eve, Jambawalikar Sachin, Liu Michael Z, Schwartz Lawrence H, Tuttle R Michael, Lee Nancy, Shukla-Dave Amita
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY.
Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH.
Tomography. 2019 Mar;5(1):15-25. doi: 10.18383/j.tom.2018.00044.
The aim of this study was to establish the repeatability measures of quantitative Gaussian and non-Gaussian diffusion metrics using diffusion-weighted imaging (DWI) data from phantoms and patients with head-and-neck and papillary thyroid cancers. The Quantitative Imaging Biomarker Alliance (QIBA) DWI phantom and a novel isotropic diffusion kurtosis imaging phantom were scanned at 3 different sites, on 1.5T and 3T magnetic resonance imaging systems, using standardized multiple b-value DWI acquisition protocol. In the clinical component of this study, a total of 60 multiple b-value DWI data sets were analyzed for test-retest, obtained from 14 patients (9 head-and-neck squamous cell carcinoma and 5 papillary thyroid cancers). Repeatability of quantitative DWI measurements was assessed by within-subject coefficient of variation (wCV%) and Bland-Altman analysis. In isotropic diffusion kurtosis imaging phantom vial with 2% ceteryl alcohol and behentrimonium chloride solution, the mean apparent diffusion (D × 10 mm/s) and kurtosis (K, unitless) coefficient values were 1.02 and 1.68 respectively, capturing in vivo tumor cellularity and tissue microstructure. For the same vial, D and K mean wCVs (%) were ≤1.41% and ≤0.43% for 1.5T and 3T across 3 sites. For pretreatment head-and-neck squamous cell carcinoma, apparent diffusion coefficient, D, D*, K, and f mean wCVs (%) were 2.38%, 3.55%, 3.88%, 8.0%, and 9.92%, respectively; wCVs exhibited a higher trend for papillary thyroid cancers. Knowledge of technical precision and bias of quantitative imaging metrics enables investigators to properly design and power clinical trials and better discern between measurement variability versus biological change.
本研究的目的是利用来自体模以及头颈部癌和甲状腺乳头状癌患者的扩散加权成像(DWI)数据,建立定量高斯和非高斯扩散指标的重复性测量方法。使用标准化的多b值DWI采集协议,在1.5T和3T磁共振成像系统上,于3个不同地点对定量成像生物标志物联盟(QIBA)DWI体模和一种新型各向同性扩散峰度成像体模进行扫描。在本研究的临床部分,对从14例患者(9例头颈部鳞状细胞癌和5例甲状腺乳头状癌)获得的60个多b值DWI数据集进行了重测分析。通过受试者内变异系数(wCV%)和Bland-Altman分析评估定量DWI测量的重复性。在含有2%十六烷基醇和山嵛基三甲基氯化铵溶液的各向同性扩散峰度成像体模小瓶中,平均表观扩散系数(D×10⁻³mm²/s)和峰度(K,无量纲)系数值分别为1.02和1.68,反映了体内肿瘤细胞密度和组织微观结构。对于同一个小瓶,1.5T和3T在3个地点的D和K平均wCVs(%)分别≤1.41%和≤0.43%。对于治疗前头颈部鳞状细胞癌,表观扩散系数、D*、K和f的平均wCVs(%)分别为2.38%、3.55%、3.88%、8.0%和9.92%;甲状腺乳头状癌的wCVs呈现出更高的趋势。了解定量成像指标的技术精度和偏差,有助于研究人员合理设计临床试验并确定其效能,更好地区分测量变异性与生物学变化。